Highlighting the controversial consequences of pro-survival pathways modulation after Notch signaling inhibition, the combination of GSI RO4929097 with oxaliplatin abrogated drug-induced apoptosis and improved survival of cancer cells, which was even more sustained by HES1 silencing. Here, HES1 is linked to cancer.